<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820858</url>
  </required_header>
  <id_info>
    <org_study_id>2012-GYN/EC-01</org_study_id>
    <nct_id>NCT01820858</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma</brief_title>
  <acronym>EC-01</acronym>
  <official_title>A Multicenter, Prospective, Randomized Trial of the Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ding Ma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial is studying the efficacy and safety of the chemotherapy compared with
      radiation therapy alone as adjuvant treatment after operation in Patients with high risk and
      Stage I endometrial carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3-year DFS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effect of adjuvant chemotherapy</measure>
    <time_frame>3-month，6-month，1-year and 3-year</time_frame>
    <description>The incidence of infusion reactions (i.e.,skin reactions, cardiovascular reactions, respiratory or throat tightness), and allergic reactions (i.e., life-threatening anaphylaxis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of radiotherapy</measure>
    <time_frame>3-month，6-month，1-year and 3-year</time_frame>
    <description>To observe the subtle effect on quality of life (e.g., diarrhea, bowel symptoms) and vaginal stenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3-month，6-month，1-year and 3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3-year OS</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel: 175 mg/m(2) intravenously (IV); followed by Paraplatin (Carboplatin Injection) AUC=5 IV. 3-6 cycles as necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Histopathological grade G3 and &lt;50% myometrial invasion: Vaginal brachytherapy 5Gy, 3 times;
Histopathological grade G3 and vascular space involvement: Pelvic radiation 45-50 Gy;
≥50% myometrial invasion: Pelvic radiation 50 Gy + Vaginal brachytherapy 5Gy, 2-4 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m(2), intravenously (IV)</description>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paraplatin (Carboplatin Injection)</intervention_name>
    <description>AUC=5, IV</description>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic Radiation</intervention_name>
    <description>45-50 Gy</description>
    <arm_group_label>Adjuvant Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Vaginal Brachytherapy 1</intervention_name>
    <description>5 Gy, 3 times</description>
    <arm_group_label>Adjuvant Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Vaginal brachytherapy 2</intervention_name>
    <description>5 Gy, 2-4 times</description>
    <arm_group_label>Adjuvant Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FIGO stage: Ⅰ, endometrial carcinoma;

          -  Female, Chinese women;

          -  Initial treatment is staging surgery;

          -  Pathological diagnosis: Endometrial adenocarcinoma;

          -  Pathologic examination and meet the following one of the indications of adjuvant
             therapy: ① histopathological grading in poorly differentiated: G3; ② ≥50% myometrial
             invasion; ③ vascular space involvement;

          -  No prior treatment;

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Unable to receive surgery and/or unsuitable for radiotherapy or chemotherapy;

          -  Family history of ovarian cancer;

          -  Suffering from other malignancies;

          -  Concurrently participating in other clinical trials;

          -  Unable or unwilling to sign informed consents;

          -  Unable or unwilling to abide by protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beihua Kong, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Qilu Hospital, Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danhui Weng, MD, PhD</last_name>
    <phone>+862783662681</phone>
    <email>weng.dh@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danhui Weng, MD</last_name>
      <phone>+862783662681</phone>
      <email>weng.dh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Changyu Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital，Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingsheng Yang, MD, Ph D</last_name>
      <phone>13791123129</phone>
      <email>xingshengyang@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Xingsheng Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuyan Mao, MD</last_name>
      <phone>13989816955</phone>
      <email>maoyy3@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yuyan Mao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of the department of Obstetrics and Gynecology, Tongji Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

